Pharmaceutical industry – Page 12
-
WebinarGaining an edge through smarter experimentation
Learn how to double your R&D capacity and get more products to market in less time – and at a lower cost
-
BusinessBiggest venture yet of any pharma company into cannabis
Jazz Pharmaceuticals buys cannabinoid therapeutic firm for $7.2 billion, inheriting first plant-derived cannabinoid medicine ever approved by FDA
-
BusinessCovid vaccination efforts bolstered by trial results from J&J and Novavax
A miserable January ended with positive news on the vaccine front but new variants added complications
-
OpinionRuling out the rule of five
Simple calculations for clinical trial success failed to find a winning formula
-
BusinessCan chemistry thaw the vaccine cold chain?
Covid-19 has highlighted the challenges of storing vaccines at their proper temperature. Angeli Mehta explores how scientists are trying to protect vaccines from heat degradation
-
BusinessVaccine approvals offer hope as global Covid cases surge
A handful of vaccines are now approved and the first doses are being given to patients, with trials for many more candidates nearing completion
-
BusinessIndustry expects problems ahead after initial relief over Brexit deal
Uncertainty still looms over regulation and logistics
-
WebinarGood practices in data analytics
Join us to learn how the University of Limerick develops skills and knowledge of data analytics via their Pharmaceutical Manufacturing Technology Centre (PMTC)
-
BusinessPharmaceuticals roundup 2020
Alongside the race for Covid-19 treatments and vaccines, the industry has maintained momentum
-
BusinessAstraZeneca to buy rare disease drugmaker Alexion in $39bn deal
Transaction would be the largest in AstraZeneca’s history
-
BusinessPfizer–BioNTech vaccine gains emergency approvals in US, Canada and beyond
UK begins vaccinating vulnerable populations after early authorisation
-
OpinionStirring in my sleep
Cut off from the lab after 40 years, Derek Lowe returns to the bench in his dreams
-
BusinessUK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
BusinessBrexit may put some chemicals out of GB’s Reach
Industry fears divergence of UK and EU regulations could spell disaster for trade
-
-
BusinessOxford–AstraZeneca vaccine joins others with promising interim data
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
-
BusinessRegulatory panel unconvinced by Alzheimer’s antibody evidence
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
-
BusinessModerna and Pfizer’s Covid-19 vaccines add more encouraging data
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy
-
ArticleThe future is bright: protecting innovation during uncertain times
The annual Pharma Integrates event facilitates conversation and collaboration to drive future innovation and improve patient outcomes worldwide
-
OpinionThe ins and outs of vaccine trials
Derek Lowe lays out how the trials work, and why they get paused and restarted